Patent Issued for Engineered retrons and methods of use (USPTO 11866728).
In: Gene Therapy Weekly, 2024-02-02, S. 3257-3257
serialPeriodical
Zugriff:
Renagade Therapeutics Management Inc. has been issued a patent for engineered retrons and their use in genome editing. Retrons are DNA sequences that produce a unique satellite DNA called msDNA, which can be used as a donor DNA template for precise genome editing. The patent describes modifications made to the retron DNA to improve its functionality and increase the concentration of msDNA. The patent also includes information on genome editing systems, nucleic acid molecules, vectors, and methods for delivering the components of the system to cells. The patent discloses a gene editing system that uses delivery vehicles containing RNA cargo to modify cells, allowing for precise genome editing and modification under various conditions. The patent also describes methods of genetically modifying cells using this system and provides compositions and formulations for pharmaceutical applications. Specific sequences and configurations for the components of the gene editing system are claimed by the inventors. For more information, refer to the patent filed by Brian Goodman. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Engineered retrons and methods of use (USPTO 11866728).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2024-02-02, S. 3257-3257 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|